IL277578A - New salt forms of URAT-1 inhibitors - Google Patents

New salt forms of URAT-1 inhibitors

Info

Publication number
IL277578A
IL277578A IL277578A IL27757820A IL277578A IL 277578 A IL277578 A IL 277578A IL 277578 A IL277578 A IL 277578A IL 27757820 A IL27757820 A IL 27757820A IL 277578 A IL277578 A IL 277578A
Authority
IL
Israel
Prior art keywords
urat
inhibitors
salt forms
novel salt
novel
Prior art date
Application number
IL277578A
Other languages
English (en)
Hebrew (he)
Original Assignee
Inventisbio Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventisbio Shanghai Ltd filed Critical Inventisbio Shanghai Ltd
Publication of IL277578A publication Critical patent/IL277578A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
IL277578A 2018-03-28 2020-09-24 New salt forms of URAT-1 inhibitors IL277578A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2018/080889 WO2019183835A1 (en) 2018-03-28 2018-03-28 Novel salt forms of urat-1 inhibitors
PCT/CN2019/079619 WO2019184897A1 (en) 2018-03-28 2019-03-26 Novel salt forms of urat-1 inhibitors

Publications (1)

Publication Number Publication Date
IL277578A true IL277578A (en) 2020-11-30

Family

ID=68059457

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277578A IL277578A (en) 2018-03-28 2020-09-24 New salt forms of URAT-1 inhibitors

Country Status (10)

Country Link
US (2) US11339127B2 (https=)
EP (1) EP3774733B1 (https=)
JP (1) JP7357634B2 (https=)
KR (1) KR102907394B1 (https=)
CN (1) CN111902398B (https=)
AU (1) AU2019241202B2 (https=)
CA (1) CA3094292A1 (https=)
IL (1) IL277578A (https=)
TW (1) TWI818001B (https=)
WO (2) WO2019183835A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234060B (zh) * 2021-04-30 2022-11-08 山东大学 一种稠杂环吡啶巯乙酸类衍生物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
TWI499412B (zh) * 2010-06-16 2015-09-11 亞德生化公司 苯基硫乙酸酯組合物及其使用方法
US8549908B2 (en) * 2010-06-17 2013-10-08 Los Robles Advertising, Inc. Thermal anemometer flow meter for the measurement of wet gas flow
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技(上海)有限公司 羧酸化合物及其制备方法和用途

Also Published As

Publication number Publication date
AU2019241202B2 (en) 2024-06-13
WO2019184897A1 (en) 2019-10-03
WO2019183835A1 (en) 2019-10-03
KR20200138260A (ko) 2020-12-09
JP2021519313A (ja) 2021-08-10
AU2019241202A1 (en) 2020-10-01
EP3774733A4 (en) 2021-12-01
EP3774733B1 (en) 2025-09-24
KR102907394B1 (ko) 2025-12-31
CN111902398B (zh) 2024-01-26
EP3774733A1 (en) 2021-02-17
CN111902398A (zh) 2020-11-06
US11685720B2 (en) 2023-06-27
US11339127B2 (en) 2022-05-24
CA3094292A1 (en) 2019-10-03
US20220371996A1 (en) 2022-11-24
US20210032204A1 (en) 2021-02-04
EP3774733C0 (en) 2025-09-24
TWI818001B (zh) 2023-10-11
JP7357634B2 (ja) 2023-10-06
TW202003467A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
SG11202106520VA (en) Kif18a inhibitors
IL270844A (en) Novel inhibitors of MAP4K1
ZA201801417B (en) Salts of an lsd1 inhibitor
IL281939A (en) VAP-1 inhibitors
IL304110A (en) Keap1–nrf2 protein–protein interaction inhibitors
IL279949A (en) Heterocyclic MCT4 inhibitors
IL281815A (en) VAP-1 inhibitors
ZA201904460B (en) Inhibitors of nhe-mediated antiport
IL276592A (en) History of Subtirum
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL269626A (en) Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
IL276312A (en) Use of Alkoxypyrazoles as nitrification inhibitors
PT3458448T (pt) Inibidores fasn para uso no tratamento de esteato-hepatite não-alcoólica
IL276013A (en) pi4kiiibeta inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
HUE067997T2 (hu) Szubsztituált 2-tiazolinok mint nitrifikációs inhibitorok
SG11202106210QA (en) Salt of syk inhibitor and crystalline form thereof
IL277869A (en) Substituted propanamides as nuclease inhibitors
IL277578A (en) New salt forms of URAT-1 inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
IL277866B1 (en) Aminothiazoles were substituted as nuclease inhibitors
SG11202101817UA (en) Methods of inhibition
IL276195A (en) Salt forms of an organic compound
SG11202104073XA (en) Malonate salt of varlitinib
PT3901141T (pt) Nova forma de isoquinolinossulfonamida